Literature DB >> 26054027

Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool.

Mark S Corbett1, Julian P T Higgins1, Nerys F Woolacott1.   

Abstract

A key component of the Cochrane Collaboration's risk of bias tool for critically evaluating randomised trials is the consideration of whether baseline characteristics of the treatment groups being compared are systematically different. Considered under the domain of 'selection bias', this is currently evaluated by looking at the methods of randomisation and specifically at the generation of the randomised allocation sequence and the concealment of this sequence during the process of randomisation. Assessment of the actual similarity of baseline variables across groups in demographic and clinical characteristics is seldom performed. Even when performed, the link with selection bias is sometimes not considered. Methods of randomisation and allocation concealment are often poorly reported in published trials, yet baseline data tables are presented in a large majority of trial reports. In this article, we propose that assessment of trial baseline data should form a key and prominent part of selection bias judgements when using the risk of bias tool. We outline the possible benefits from using this approach, including reduced uncertainty in systematic review conclusions, reduced risk of chance findings being ascribed to treatment effects and better use of available evidence by a more considered approach to evaluating studies using imperfect randomisation and allocation methods.
Copyright © 2013 John Wiley & Sons, Ltd.

Keywords:  Cochrane Collaboration; baseline imbalance; randomised trials; risk of bias; systematic reviews

Mesh:

Year:  2013        PMID: 26054027     DOI: 10.1002/jrsm.1090

Source DB:  PubMed          Journal:  Res Synth Methods        ISSN: 1759-2879            Impact factor:   5.273


  61 in total

Review 1.  Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials.

Authors:  Wen-Qi Ma; Yu Zhao; Ying Wang; Xi-Qiong Han; Yi Zhu; Nai-Feng Liu
Journal:  Int Urol Nephrol       Date:  2018-02-05       Impact factor: 2.370

2.  Calcium, vitamin D or recombinant parathyroid hormone for managing post-thyroidectomy hypoparathyroidism.

Authors:  Ovie Edafe; Claudia E Mech; Sabapathy P Balasubramanian
Journal:  Cochrane Database Syst Rev       Date:  2019-05-22

Review 3.  Comparative efficacy of cartilage repair procedures in the knee: a network meta-analysis.

Authors:  Jonathan C Riboh; Gregory L Cvetanovich; Brian J Cole; Adam B Yanke
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-09-07       Impact factor: 4.342

Review 4.  Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; David Peick Sonne; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2016-10-17

Review 5.  Botulinum toxin type A therapy for cervical dystonia.

Authors:  Mafalda Castelão; Raquel E Marques; Gonçalo S Duarte; Filipe B Rodrigues; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2017-12-12

Review 6.  Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.

Authors:  Gonçalo S Duarte; Mafalda Castelão; Filipe B Rodrigues; Raquel E Marques; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2016-10-26

7.  Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.

Authors:  Kasper S Madsen; Pernille Kähler; Lise Katrine Aronsen Kähler; Sten Madsbad; Filip Gnesin; Maria-Inti Metzendorf; Bernd Richter; Bianca Hemmingsen
Journal:  Cochrane Database Syst Rev       Date:  2019-04-18

Review 8.  Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; Jesper Krogh; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2016-04-21

9.  Botulinum toxin type A therapy for blepharospasm.

Authors:  Gonçalo S Duarte; Filipe B Rodrigues; Raquel E Marques; Mafalda Castelão; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2020-11-19

10.  Transcatheter versus surgical aortic valve replacement in low and intermediate risk patients with severe aortic stenosis: systematic review and meta-analysis of randomized controlled trials and propensity score matching observational studies.

Authors:  Jintao Fu; Mohammad Sharif Popal; Yulin Li; Guoqi Li; Yue Qi; Fang Fang; Joey S W Kwong; Bin You; Xu Meng; Jie Du
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.